Oncology

The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

Individuals treated with the drugs from AstraZeneca demonstrate clinically meaningful and statistically significant improvement.

The overall survival hazard ratio numerically favored niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort in patients with platinum-sensitive recurrent ovarian cancer.

Brianna Hawkins, MBA, a University of Tennessee Health Science Center doctor of pharmacy candidate, discusses oncology drug development and how students can start a career in this alternative path.

It would also be beneficial to include a patient’s entire healthcare team in this management strategy, said an expert at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2023 in Phoenix, Arizona.

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.

Consistent toxicity management and education reinforcement can improve the patient’s treatment management strategy.

The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

Expert discusses the updated guidelines for treating diabetes at the American Pharmacists Association (APhA) 2023 Meeting & Exposition in Phoenix, Arizona.

Stephen Divers, MD, discussed the future of home infusion and drug development, and how both issues will be influential in the future of community pharmacy.

Improving the process of safe medication therapy management requires comfort, trust, and fostering a culture for safe communication.

Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Seagen Inc) with pembrolizumab (Keytruda, Merck) approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Additionally, study results show a clinically meaningful overall survival trend in the overall population among individuals with primary advanced or recurrent disease.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

A strong theme of recent conferences was the push for greater awareness of pharmacists' roles in patient advocacy and patient education.

Some common questions for oncology pharmacists are about concurrent use of complementary and alternative medicine supplements and natural products.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

Factors (comorbidities, social factors) can largely affect the success of therapies in daily practice, despite findings observed in clinical trials.

And whatever specialty the student or resident decides on, it does not have to define the rest of their career.

Creating a safe environment for LGBTQ+ patients through the use of trauma informed care is critical to ensuring they feel comfortable returning to the clinic in the future.

There has been a historical lack of complete or appropriate data on sexual and gender minority groups, leading to difficulties in analyzing health outcomes in LGBTQ+ community.

Despite the potential for clinical benefit, triplet therapies have added complexities, monitoring needs, toxicities, and costs associated with additional pharmacologic therapy.

If patients with G6PD deficiency are exposed to risk factors, such as certain medications, environmental factors, or foods, it can lead to hemolysis.

Pharmacists have an important role in helping patients to identify treatment-related toxicities and manage symptoms to help the transition to the outpatient setting.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

The Hematology/Oncology Pharmacy Association (HOPA) created committees, inclusion statements, and diversity, equity, and inclusion (DEI) checkpoints to improve healthcare for underserved or historically less included populations.

Before tapering patients treated for cancer off of opioids, care providers should first establish what the goals of tapering are.